Visceral adipose tissue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
=== Radioactive beach hypothesis === Zachary Adam claims that tidal processes that occurred during a time when the Moon was much closer may have concentrated grains of uranium and other radioactive elements at the high-water mark on primordial beaches, where they may have been responsible for generating life's building blocks. According to computer models, a deposit of such radioactive materials could show the same self-sustaining nuclear reaction as that found in the Oklo uranium ore seam in Gabon. Such radioactive beach sand might have provided sufficient energy to generate organic molecules, such as amino acids and sugars from acetonitrile in water. Radioactive monazite material also has released soluble phosphate into the regions between sand-grains, making it biologically "accessible." Thus amino acids, sugars, and soluble phosphates might have been produced simultaneously, according to Adam. Radioactive actinides, left behind in some concentration by the reaction, might have formed part of organometallic complexes. These complexes could have been important early catalysts to living processes. John Parnell has suggested that such a process could provide part of the "crucible of life" in the early stages of any early wet rocky planet, so long as the planet is large enough to have generated a system of plate tectonics which brings radioactive minerals to the surface. As the early Earth is thought to have had many smaller plates, it might have provided a suitable environment for such processes.
{\displaystyle {\begin{aligned}x:\ &\rho \left({\partial _{t}u_{x}}+u_{x}\,{\partial _{x}u_{x}}+u_{y}\,{\partial _{y}u_{x}}+u_{z}\,{\partial _{z}u_{x}}\right)\\&\quad =-\partial _{x}p+\mu \left({\partial _{x}^{2}u_{x}}+{\partial _{y}^{2}u_{x}}+{\partial _{z}^{2}u_{x}}\right)+{\frac {1}{3}}\mu \ \partial _{x}\left({\partial _{x}u_{x}}+{\partial _{y}u_{y}}+{\partial _{z}u_{z}}\right)+\rho g_{x}\\\end{aligned}}}
Among the extreme claims used to market goji berries or its juice, often referred to as a "superfruit", is the unsupported story that a Chinese man named Li Qing Yuen, who was said to have consumed wolfberries daily, lived to the age of 256 years (1677–1933). This claim originated in a 2003 booklet by Mindell, who also claimed goji had anti-cancer properties. The booklet contained false and unverified claims. On 29 May 2009, a class action lawsuit was filed against FreeLife in the United States District Court of Arizona. This lawsuit alleged false claims, misrepresentations, false and deceptive advertising, and other issues regarding FreeLife's Himalayan Goji Juice, GoChi, and TaiSlim products. This lawsuit sought remedies for consumers who had purchased the products over the years. A settlement agreement was reached on 28 April 2010, where FreeLife took steps to ensure that its goji products were not marketed as "unheated" or "raw", and made a contribution to an educational organization. As with many other novel "health" foods and supplements, the lack of clinical evidence and poor quality control in the manufacture of consumer products prevent goji from being clinically recommended or applied.
Dershowitz replied to the invitation that he would not attend if it was a "victory party", and von Bülow assured him that it was only a dinner for "several interesting friends". Norman Mailer also attended the dinner where Dershowitz explained why the evidence pointed to von Bülow not having attempted to murder his wife. As Dershowitz recounted, Mailer grabbed the arm of his wife, Norris Church Mailer, and said: "Let's get out of here. I think this guy is innocent. I thought we were going to be having dinner with a man who actually tried to kill his wife. This is boring." After his acquittal, von Bülow made his home in London while making occasional appearances at Broadway opening nights and other Manhattan social events for the rest of his life.
Sources: en.wikipedia.org
Methandienone binds to and activates the androgen receptor (AR) in order to exert its effects. These include dramatic increases in protein synthesis, glycogenolysis, and muscle strength over a short space of time. While it can be metabolized by 5α-reductase into methyl-1-testosterone (17α-methyl-δ1-DHT), a more potent AAS, the drug has extremely low affinity for this enzyme and methyl-1-testosterone is thus produced in only trace amounts. As such, 5α-reductase inhibitors like finasteride and dutasteride do not reduce the androgenic effects of metandienone. Nonetheless, while the ratio of anabolic to androgenic activity of metandienone is improved relative to that of testosterone, the drug does still possess moderate androgenic activity and is capable of producing severe virilization in women and children. As such, it is only really commonly used in men. Metandienone is a substrate for aromatase and can be metabolized into the estrogen methylestradiol (17α-methylestradiol). While the rate of aromatization is reduced relative to that for testosterone or methyltestosterone, the estrogen produced is metabolism-resistant and hence metandienone retains moderate estrogenic activity. As such, it can cause side effects such as gynecomastia and fluid retention. The co-administration of an antiestrogen such as an aromatase inhibitor like anastrozole or a selective estrogen receptor modulator like tamoxifen can reduce or prevent such estrogenic side effects. Metandienone has no progestogenic activity.
Mutations may produce unstable antithrombins that either may be not exported into the blood correctly upon completion biosynthesis or exist in the blood for a shortened period of time, e.g., the deletion of 6 base pairs in codons 106–108. Minor insertions or deletions may lead to frame shift mutations and premature termination of the antithrombin gene. Point mutations may also result in the premature generation of a termination or stop codon e.g. the mutation of codon 129, CGA→TGA (UGA after transcription), replaces a normal codon for arginine with a termination codon. Mutations near the intron-exon border and in non-coding regions can lead to aberrant splicing. In a small percentage of antithrombin deficiency cases, no (likely) pathogenic variants can be found in the SERPINC1 gene. There is evidence that post-translational glycosylation defects can explain the antithrombin deficiency in some of these cases.
==== Primary antibody ==== The primary antibodies are generated when a host species or immune cell culture is exposed to the protein of interest (or a part thereof). Normally, this is part of the immune response, whereas here they are harvested and used as sensitive and specific detection tools that bind the protein directly. After blocking, a solution of primary antibody (generally between 0.5 and 5 micrograms/mL) diluted in either PBS or TBST wash buffer is incubated with the membrane under gentle agitation for typically an hour at room temperature, or overnight at 4°C. It can also be incubated at different temperatures, with lesser temperatures being associated with more binding, both specific (to the target protein, the "signal") and non-specific ("noise"). Following incubation, the membrane is washed several times in wash buffer to remove unbound primary antibody, and thereby minimize background. Typically, the wash buffer solution is composed of buffered saline solution with a small percentage of detergent, and sometimes with powdered milk or BSA.
=== Biosynthesis === Formic acid is named after ants which have high concentrations of the compound in their venom, derived from serine through a 5,10-methenyltetrahydrofolate intermediate. The conjugate base of formic acid, formate, also occurs widely in nature. An assay for formic acid in body fluids, designed for determination of formate after methanol poisoning, is based on the reaction of formate with bacterial formate dehydrogenase.
=== Other functions === EF-Tu has been found in large quantities in the cytoskeletons of bacteria, co-localizing underneath the cell membrane with MreB, a cytoskeletal element that maintains cell shape. Defects in EF-Tu have been shown to result in defects in bacterial morphology. Additionally, EF-Tu has displayed some chaperone-like characteristics, with some experimental evidence suggesting that it promotes the refolding of a number of denatured proteins in vitro. EF-Tu has been found to moonlight on the cell surface of the pathogenic bacteria Staphylococcus aureus, Mycoplasma pneumoniae, and Mycoplasma hyopneumoniae, where EF-Tu is processed and can bind to a range of host molecules. In Bacillus cereus, EF-Tu also moonlights on the surface, where it acts as an environmental sensor and binds to substance P.
Sources: en.wikipedia.org
The British Phosphate Commissioners (BPC) was a board of Australian, British, and New Zealand representatives who managed extraction of phosphate from Christmas Island, Nauru, and Banaba (Ocean Island) from 1920 until 1981. Nauru was a mandate territory governed on behalf of Nauru by Australia, Britain and New Zealand. However, representatives on the Permanent Mandates Commission argued that the activities of the BPC on Nauru were exploitative and not to the benefit of Nauruans. Australia intentionally suppressed information about its activities in Nauru. In 1968, Nauru brought Australia up before the International Court of Justice over the environmental devastation that they had caused on Nauru.
==== Polymer-based delivery systems ==== Vaccine antigens are often encapsulated within microspheres or liposomes. Common microspheres made using Poly-lactic acid (PLA) and poly-lactic-co-glycolic acid (PLGA) allow for controlled antigen release by degrading in vivo while liposomes including multilamellar or unilamellar vesicles allow for prolonged release. Polymer-based delivery systems confer advantages such as increased resistance to degradation in GI tract, controlled antigen release, raised particle uptake by immune cells and enhanced ability to induce cytotoxic T cell responses. An example of licensed recombinant vaccine utilising liposomal delivery is Shringrix.
Porous glass is glass that includes pores, usually in the nanometre- or micrometre-range, commonly prepared by one of the following processes: through metastable phase separation in borosilicate glasses (such as in their system SiO2-B2O3-Na2O), followed by liquid extraction of one of the formed phases; through the sol-gel process; or simply by sintering glass powder. The specific properties and commercial availability of porous glass make it one of the most extensively researched and characterized amorphous solids. Due to the possibility of modeling the microstructure, porous glasses have a high potential as a model system. They show a high chemical, thermal and mechanical resistance, which results from a rigid and incompressible silica network. They can be produced in high quality and with pore sizes ranging from 1 nm up to any desired value. An easy functionalization of the inner surface opens a wide field of applications for porous glasses. A further special advantage of porous glasses compared to other porous materials, is that they can be made not only as powder or granulate, but also as larger pieces in almost any user defined shape and texture.
Narrated by Bill Paterson, directed by Paul Sen, produced by Rosalind Arden, made by McDougall Craig 22 September Non-lethal Weapon, about non-lethal weapons; Steven Metz of the US Army War College; Ride of the Valkyries with sticky foam guns; a net gun made by Foster-Miller; sonic weapons; Jonathan Rosenhead of the LSE; seventeen people had been killed by plastic bullets in Northern Ireland; Lenore Anderson; in the Gulf War air campaign of 1991, Tomahawk missiles discharged BLU-114/B wire over Iraq electrical substations, and crippled 85% of the country's electrical network, so effectively switching off the country's air defence radar; Julian Perry Robinson of the Science Policy Research Unit at the University of Sussex. Produced by David Frank, directed by Martin Durkin, made by RDF Television with Discovery Communications
== Advantages == Explained previously by (Lee, Choe, Aggarwal, 2017). A key benefit of isobaric labeling over other quantification techniques (e.g. label-free) is the multiplex capabilities and thus increased throughput potential. The ability to combine and analyze several samples simultaneously in one LC-MS run eliminates the need to analyze multiple data sets and eliminates run-to-run variation. Multiplexing reduces sample processing variability, improves specificity by quantifying the peptides from each condition simultaneously, and reduces turnaround time for multiple samples. Without multiplexing, information can be missed from run to run, affecting identification and quantification, as peptides selected for fragmentation on one LC-MS/MS run may not be present or of suitable quantity in subsequent sample runs. The current available isobaric chemical tags facilitate the simultaneous analysis of 2 to 11 experimental samples.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.